Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Manuel Espinoza-Gutarra, Omer Jamy, Razan Mohty, Lauren Kelly Shea, Donna Salzman, Antonio Di Stasi, Ravi Bhatia, Zaid Al-Kadhimi, Sumithira Vasu

Blood (2024) 144 (Supplement 1): 7290.

https://doi.org/10.1182/blood-2024-206687

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Manuel Espinoza-Gutarra, Ravi Bhatia, Zaid Al-Kadhimi, Omer Jamy

Blood (2023) 142 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2023-184658

Published: 2023

Journal Articles

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Omer H Jamy, Kendall Diebold, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Kelly N. Godby, Donna Salzman, Ravi Bhatia

Blood (2022) 140 (Supplement 1): 8959–8960.

https://doi.org/10.1182/blood-2022-160346

Published: 2022

Journal Articles

Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

Gayathri Ravi, Smith Giri, Susan Bal, Kelly N. Godby, Vishnu V.B. Reddy, Donna Salzman, Omar Alkharabsheh, Scott A. McDaniel, Melissa Sentell, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 8048–8049.

https://doi.org/10.1182/blood-2022-170099

Published: 2022

Journal Articles

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Nicole Watts, Courtney Hebert, Clare Ubersax, Deanna Clark, Gayathri Ravi, Susan Bal, Purnima Singh, Kelly N. Godby, Donna Salzman, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 5248–5249.

https://doi.org/10.1182/blood-2022-163649

Published: 2022

Journal Articles

Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report

Blood (2021) 138 (Supplement 1): 484.

https://doi.org/10.1182/blood-2021-149720

Published: 2021

Journal Articles

A Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Older Patients Using Fludarabine and Total Body Irradiation

Omer Hassan Jamy, Sankalp Arora, Donna Salzman, Antonio Di Stasi, Kentaro Minagawa, Shin Mineishi, Ayman Saad

Blood (2021) 138 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2021-151153

Published: 2021

Journal Articles

Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation

Omer Hassan Jamy, John Dasher, Yanjun Chen, Kevin D. Battles, Donna Salzman, Antonio Di Stasi, Ravi Bhatia, Smita Bhatia

Blood (2021) 138 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2021-145234

Published: 2021

Journal Articles

Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS)

Nora Balas, Lindsey Hageman, Jessica Wu, Liton F. Francisco, Elizabeth Schlichting, Alysia Bosworth, Hok Sreng Te, Lennie Wong, Wendy Landier, Donna Salzman, Daniel J. Weisdorf, Stephen J Forman, Mukta Arora, Saro H. Armenian, Smita Bhatia

Blood (2021) 138 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2021-146191

Published: 2021

Journal Articles

Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report

Andrew McDonald, Chen Dai, Lindsey Hageman, Wendy Landier, Jessica Wu, Elizabeth Schlichting, Nora Balas, Liton F. Francisco, Alysia Bosworth, Hok Sreng Te, Lennie Wong, Donna Salzman, Ravi Bhatia, Daniel J. Weisdorf, Stephen J Forman, Mukta Arora, Saro H. Armenian, Smita Bhatia

Blood (2021) 138 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2021-146872

Published: 2021

Journal Articles

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Omer Jamy, MD, Racquel Innis-Shelton, MD, Susan Bal, MDMBBS, Ravi K. Paluri, MD, Samina Karim, Joseph H. Chewning, MD, Donna Salzman, MD, Luciano J. Costa, MD PhD, Antonio Di Stasi, MD, Lawrence S. Lamb, Jr., PhD, Shin Mineishi, Ayman Saad, MD

Blood (2019) 134 (Supplement_1): 2003.

https://doi.org/10.1182/blood-2019-129536

Published: 2019

Journal Articles

Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report

Anna Sällfors Holmqvist, Yanjun Chen, Jessica Wu, Kevin Battles, Ravi Bhatia, Liton Francisco, Lindsey Hageman, Michelle Kung, Emily Ness, Mariel Parman, Donna Salzman, Jeanette Falck Winther, Joseph Rosenthal, Stephen J. Forman, Daniel J. Weisdorf, Mukta Arora, Saro H. Armenian, Smita Bhatia

Blood (2018) 131 (24): 2720–2729.

https://doi.org/10.1182/blood-2018-02-831156

Published: 2018

Includes: Supplemental data

Journal Articles

Reduction in Late Mortality after Autologous Blood or Marrow Transplantation (autoBMT) in Childhood - a Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2)

Anna Sallfors Holmqvist, MD PhD, Yanjun Chen, MS, Jessica Wu, BA, Lindsey Hageman, MPH, Liton F. Francisco, BS, Mariel Parman, MPH, Michelle Kung, MA, Emily Ness, MPH, Kevin D. Battles, BS, Jeanette Falck Winther, MD DMSc, Joseph Rosenthal, MD MS, Ravi Bhatia, MD, Donna Salzman, MD, Stephen J. Forman, MD FACP, Daniel J. Weisdorf, MD, Saro H. Armenian, DO,MPH, Mukta Arora, MD, Smita Bhatia, MDMPH

Blood (2017) 130 (Supplement 1): 337.

https://doi.org/10.1182/blood.V130.Suppl_1.337.337

Published: 2017

Journal Articles

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Luciano J. Costa, MD PhD, Racquel Innis-Shelton, MD, Joscelyn Bowersock, MT, Ayman Saad, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Nicole Watts, PharmD, Lawrence S. Lamb, Jr., PhD

Blood (2017) 130 (Supplement 1): 4708.

https://doi.org/10.1182/blood.V130.Suppl_1.4708.4708

Published: 2017

Journal Articles

Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood: a Report from the BMT Survivor Study-2 (BMTSS-2)

Anna Sallfors Holmqvist, MD PhD, Yanjun Chen, MS, Jessica Wu, BA, Lindsey Hageman, MPH, Liton F. Francisco, BS, Mariel Parman, MPH, Michelle Kung, MA, Emily Ness, MPH, Kevin D. Battles, BS, Ravi Bhatia, MD, Donna Salzman, MD, Jeanette Falck Winther, MD DMSc, Stephen J. Forman, MD, Joseph Rosenthal, MD MS, Daniel J. Weisdorf, MD, Saro H. Armenian, DO,MPH, Mukta Arora, MD, Smita Bhatia, MDMPH

Blood (2017) 130 (Supplement 1): 672.

https://doi.org/10.1182/blood.V130.Suppl_1.672.672

Published: 2017

Journal Articles

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD PhD, Heather Landau, MD, Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Donna Salzman, MD, Ayman Saad, MD, Racquel Innis-Shelton, MD, Mehdi Hamadani, MD, Roni Tamari, MD, Kelly N. Godby, MD, Vladimir Petrovic, Lisa Williams, RN, Evelyn Orlando, Pamela M Dixon, RN, Sergio A. Giralt, MD

Blood (2016) 128 (22): 4630.

https://doi.org/10.1182/blood.V128.22.4630.4630

Published: 2016

Journal Articles

Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD

Paluri k Ravi, Samina Karim, Gretchen Cloud, Mary Lamb, Samantha Langford, Shin Mineishi, MD, Racquel-innis Shelton, Ayman Saad, MD, Donna Salzman, MD, Lawrence S. Lamb, PhD

Blood (2014) 124 (21): 2474.

https://doi.org/10.1182/blood.V124.21.2474.2474

Published: 2014

Journal Articles

Influence of Pre-Transplant Cytomegalovirus (CMV) Serostatus on Post-Transplant Viral Reactivation after Allogeneic Stem Cell Transplantation in Patients Receiving Post-Transplant Cyclophosphamide for Gvhd Prophylaxis

Ravi K. Paluri, MD, Racquel Shelton, Melissa Gazi, Lawrence S. Lamb, PhD, Ayman Saad, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Shin Mineishi, MD

Blood (2014) 124 (21): 3864.

https://doi.org/10.1182/blood.V124.21.3864.3864

Published: 2014

Journal Articles

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Racquel Innis-Shelton, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Lawrence S. Lamb, PhD, Melissa Gazi, Lisa Williams, RN, Luciano J Costa, MD PhD, Harry Erba, Shin Mineishi, MD, Ayman Saad, MD

Blood (2014) 124 (21): 3911.

https://doi.org/10.1182/blood.V124.21.3911.3911

Published: 2014

NARROW

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report

A Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Older Patients Using Fludarabine and Total Body Irradiation

Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation

Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS)

Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report

Reduction in Late Mortality after Autologous Blood or Marrow Transplantation (autoBMT) in Childhood - a Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2)

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood: a Report from the BMT Survivor Study-2 (BMTSS-2)

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD

Influence of Pre-Transplant Cytomegalovirus (CMV) Serostatus on Post-Transplant Viral Reactivation after Allogeneic Stem Cell Transplantation in Patients Receiving Post-Transplant Cyclophosphamide for Gvhd Prophylaxis

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only